BrickBio

BrickBio is a Boston-based biotechnology company leveraging its site-specific and site-selective platform to enable next-generation unnatural amino acid conjugated protein conjugates. The platform technology spans both prokaryotic and eukaryotic expression systems, allowing for the development of unique biologics and protein therapeutics with enhanced properties, including improved half-life, dosing, and efficacy. BrickBio boasts the most comprehensive bioconjugation toolkit, capable of optimizing any conjugate, and is uniquely positioned to advance the field of biologics by selectively modifying multiple distinct sites on individual proteins. BrickBio is expanding its therapeutic programs to include ADCs, bispecific conjugates, and novel scaffolds.